Cancer-focused Black Diamond vaults on to Nasdaq in $200M+ public debut, marking biggest biotech IPO in 2020 so far

Versant-backed Black Diamond Therapeutics has set its sights on an upsized biotech IPO to kick 2020 off.

The first startup out of Versant’s

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Can­cer-fo­cused Black Di­a­mond vaults on to Nas­daq in $200M+ pub­lic de­but, mark­ing biggest biotech IPO in 2020 so far